Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Given the high death rate the first two months of tuberculosis (TB) therapy in HIV patients, it is critical defining the optimal time to initiate combination antiretroviral therapy (cART).A randomized, open-label, clinical trial comparing efficacy and safety of efavirenz-based cART initiated one wee...
Main Authors: | Wondwossen Amogne, Getachew Aderaye, Abiy Habtewold, Getnet Yimer, Eyasu Makonnen, Alemayhu Worku, Anders Sonnerborg, Eleni Aklillu, Lars Lindquist |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4429073?pdf=render |
Similar Items
-
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
by: Getnet Yimer, et al.
Published: (2011-01-01) -
Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients.
by: Getnet Yimer, et al.
Published: (2008-03-01) -
Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.
by: Getnet Yimer, et al.
Published: (2014-01-01) -
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
by: Sabina Mugusi, et al.
Published: (2020-02-01) -
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
by: Eliford Ngaimisi, et al.
Published: (2013-01-01)